CSL Licenses Lixudebart in $355 Million Initial Deal
CSL and Alentis entered a global collaboration to develop and promote lixudebart, an antibody against exposed claudin-1. CSL will make a $355 million initial payment, fund specified trials and may pay up to $1.2…
